--- title: "MetaVia | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286461115.md" datetime: "2026-05-14T20:15:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286461115.md) - [en](https://longbridge.com/en/news/286461115.md) - [zh-HK](https://longbridge.com/zh-HK/news/286461115.md) --- # MetaVia | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.79, missing the estimate of USD -0.755. EBIT: As of FY2026 Q1, the actual value is USD -4.11 M. #### Research and Development (R&D) Expenses MetaVia Inc.’s R&D expenses were approximately $2.1 million for the first quarter ended March 31, 2026, marking a decrease of approximately $0.2 million from $2.3 million in the prior year’s period. This reduction was primarily due to a $0.1 million decrease in direct R&D expenses related to vanoglipel product development and a $0.1 million decrease in indirect employee compensation and benefits costs. Direct R&D costs included $0.7 million for the three months ended March 31, 2026, and $1.1 million for the three months ended March 31, 2025, primarily for investigational drug manufacturing, non-clinical, and preclinical costs under the Shared Services Agreement with Dong-A ST. #### General and Administrative (G&A) Expenses G&A expenses for MetaVia Inc. increased by approximately $0.3 million to $1.9 million for the first quarter ended March 31, 2026, compared to $1.6 million for the corresponding period in 2025. This increase was mainly driven by approximately $0.1 million higher consulting expenditures, $0.1 million higher franchise tax expenses, and $0.1 million higher legal and professional fees. #### Total Operating Expenses Total operating expenses for MetaVia Inc. were approximately $4.0 million for the first quarter ended March 31, 2026, representing an increase of approximately $0.1 million from $3.9 million for the first quarter ended March 31, 2025. This rise was primarily attributed to higher G&A expenses, partially offset by lower R&D expenses. #### Total Other Income Total other income for MetaVia Inc. was approximately $0.2 million for the first quarter ended March 31, 2026, consistent with the corresponding period in 2025. This included a gain from change in fair value of warrant liabilities of $0.117 million in Q1 2026, compared to $0.087 million in Q1 2025, and net interest income of $0.085 million in Q1 2026, compared to $0.128 million in Q1 2025. #### Net Loss MetaVia Inc. reported a net loss of - $3.8 million for the first quarter ended March 31, 2026, compared to a net loss of - $3.7 million for the first quarter ended March 31, 2025. #### Cash and Cash Equivalents Cash and cash equivalents for MetaVia Inc. totaled $13.7 million as of March 31, 2026, an increase from $10.2 million as of December 31, 2025. #### Operational Highlights In May 2026, MetaVia Inc. announced the presentation of additional data from the 48 mg Phase 1 trial of DA-1726 at the EASL Congress 2026. The company dosed the first patient in Part 3 of the Phase 1 clinical trial evaluating DA-1726 in obese adults in April 2026, assessing one-step titration to 48 mg and two-step titration to 64 mg, following IRB approval for the 16-week titration study in March 2026. MetaVia Inc. also announced a global intellectual property portfolio for vanoglipel in March 2026, with 48 granted and pending patents providing protection into 2035, and strengthened its global intellectual property position for DA-1726 in February 2026, with 39 granted and pending patents offering protection through at least 2041. Positive AI-modeling results for vanoglipel from the collaboration with Syntekabio, Inc. were announced in February 2026, and in January 2026, the company closed an underwritten public offering for gross proceeds of approximately $9.3 million. Additionally, MetaVia Inc. announced positive, statistically significant results in January 2026 from the 8-week non-titrated 48 mg MAD cohort of the Phase 1 clinical trial of DA-1726, demonstrating robust early weight loss, reductions in waist circumference, improved glucose control, and reduced liver stiffness. #### Outlook / Guidance MetaVia Inc. anticipates a data readout from the Phase 1 Part 3, 16-week titration studies for DA-1726 in obesity, evaluating 48 mg and 64 mg regimens, in the fourth quarter of 2026. The company is currently working to schedule an end-of-Phase 2 meeting with the FDA for vanoglipel (DA-1241) in MASH. MetaVia Inc. expects its current cash position to be adequate to fund operations into the fourth quarter of 2026. ### Related Stocks - [MTVA.US](https://longbridge.com/en/quote/MTVA.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)